AR106908A1 - Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación - Google Patents
Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulaciónInfo
- Publication number
- AR106908A1 AR106908A1 ARP160103699A ARP160103699A AR106908A1 AR 106908 A1 AR106908 A1 AR 106908A1 AR P160103699 A ARP160103699 A AR P160103699A AR P160103699 A ARP160103699 A AR P160103699A AR 106908 A1 AR106908 A1 AR 106908A1
- Authority
- AR
- Argentina
- Prior art keywords
- compositions
- methods
- cytoquine
- immunor
- regulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
La presente descripción proporciona composiciones de anticuerpo injertadas con citoquina, incluyendo, por ejemplo, constructos injertados que se unen a y estimulan la señalización intracelular a través de un miembro de la super-familia del receptor de interleucina (es decir, lL10R1), y estimulan la señalización. Composiciones proporcionadas encuentran uso en la mejora de respuestas de células anti-inflamatorias, y relativamente reducen los efectos pro-inflamatorios en el tratamiento, mejora y prevención de trastornos relacionados con el sistema inmune que pueden ser contrarrestados con una respuesta anti-inflamatoria aumentada. Adicionalmente, se proporcionan polinucleótidos y vectores que codifican tales moléculas y células huésped capaces de producir moléculas, así como también métodos de fabricación y uso de composiciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562263008P | 2015-12-04 | 2015-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106908A1 true AR106908A1 (es) | 2018-02-28 |
Family
ID=57543103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103699A AR106908A1 (es) | 2015-12-04 | 2016-12-02 | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación |
Country Status (25)
Country | Link |
---|---|
US (3) | US10144768B2 (es) |
EP (1) | EP3383891A1 (es) |
JP (2) | JP6794448B2 (es) |
KR (2) | KR102213790B1 (es) |
CN (1) | CN108602870A (es) |
AR (1) | AR106908A1 (es) |
AU (1) | AU2016362777B2 (es) |
BR (1) | BR112018010937A2 (es) |
CA (1) | CA3006477A1 (es) |
CL (1) | CL2018001427A1 (es) |
CO (1) | CO2018005678A2 (es) |
CU (1) | CU20180047A7 (es) |
EA (1) | EA201891341A1 (es) |
EC (1) | ECSP18041733A (es) |
IL (1) | IL259529A (es) |
MA (1) | MA43372A (es) |
MX (1) | MX2018006778A (es) |
PE (1) | PE20181358A1 (es) |
PH (1) | PH12018501160A1 (es) |
RU (1) | RU2018124307A (es) |
SA (1) | SA518391711B1 (es) |
SG (1) | SG11201804259UA (es) |
TW (1) | TW201726716A (es) |
UY (1) | UY37003A (es) |
WO (1) | WO2017093947A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
EP3630162A1 (en) * | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
WO2018215937A1 (en) * | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
CN110662762A (zh) * | 2017-05-24 | 2020-01-07 | 诺华股份有限公司 | 抗体细胞因子移植蛋白和用于治疗癌症的方法 |
CN109521192B (zh) * | 2018-11-27 | 2021-07-13 | 柏荣诊断产品(上海)有限公司 | 一种提高胶乳比浊试剂检测灵敏度的方法 |
EP3934681A4 (en) * | 2019-03-06 | 2023-12-20 | Deka Biosciences, Inc. | IL-10 VARIANT MOLECULES AND METHODS OF TREATMENT OF INFLAMMATORY DISEASE AND ONCOLOGY |
CN114206383A (zh) * | 2019-06-10 | 2022-03-18 | 武田药品工业株式会社 | 用于抗体生产的细胞培养方法和组合物 |
JP2022541156A (ja) * | 2019-07-08 | 2022-09-22 | プロジェン・カンパニー・リミテッド | 新規il-10変異体タンパク質及びその用途 |
CN110472294B (zh) * | 2019-07-19 | 2022-09-30 | 河南科技大学 | 一种嫁接涡旋光束的掩模板的设计方法 |
CN116615462A (zh) | 2020-11-23 | 2023-08-18 | 诺华股份有限公司 | 抗体构建体的表达技术 |
EP4330383A1 (en) | 2021-04-29 | 2024-03-06 | Novartis AG | Hypersialylating cells |
TW202325746A (zh) * | 2021-11-02 | 2023-07-01 | 大陸商廣東菲鵬製藥股份有限公司 中國廣東省東莞市松山湖園區桃園路1號10棟301室 郵編:523808 | Il10單體融合蛋白及其應用 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
EP0517895B1 (en) | 1990-12-14 | 1996-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
CZ25697A3 (en) | 1994-07-29 | 1997-09-17 | Smithkline Beecham Plc | Novel compounds |
JPH11501506A (ja) | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2340112T3 (es) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
US7279462B1 (en) | 1998-04-27 | 2007-10-09 | Nevagen Llc | Somatic transgene immunization and related methods |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
WO2002044197A2 (en) | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
CA2436671C (en) * | 2000-12-05 | 2015-02-03 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
EP1572937B1 (en) | 2002-04-09 | 2012-02-08 | The Scripps Research Institute | Motif-grafted hybrid polypeptides and uses thereof |
US8603472B2 (en) * | 2002-04-09 | 2013-12-10 | The Curators Of The University Of Missouri | Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide |
WO2003086286A2 (en) | 2002-04-09 | 2003-10-23 | The Curators Of The University Of Missouri | Treatment of type 1 diabetes before and after expression of predisposition markers |
US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
EP1638581A2 (en) | 2003-03-31 | 2006-03-29 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
WO2004108078A2 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals Inc. | Rationally designed antibodies |
US7981843B2 (en) | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
ES2744149T3 (es) | 2004-11-16 | 2020-02-21 | Humanigen Inc | Intercambio de casetes de la región variable de la inmunoglobulina |
GEP20156390B (en) | 2008-01-03 | 2015-11-10 | Scripps Research Inst | Antibody targeting through a modular recognition domain |
KR20110122846A (ko) | 2009-02-24 | 2011-11-11 | 알렉시온 파마슈티칼스, 인코포레이티드 | 치료용 tpo/epo 모방 펩티드를 포함하는 항체 |
KR20120053042A (ko) | 2009-08-17 | 2012-05-24 | 로슈 글리카트 아게 | 표적화된 면역접합체 |
CN102666875A (zh) | 2009-10-15 | 2012-09-12 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
US8956607B2 (en) | 2009-11-30 | 2015-02-17 | Biotest Ag | Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE) |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
WO2012045334A1 (en) * | 2010-10-05 | 2012-04-12 | Synthon Bv | Biologically active il-10 fusion proteins |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
EP2672999A2 (en) | 2011-02-10 | 2013-12-18 | Roche Glycart AG | Improved immunotherapy |
LT3489255T (lt) | 2011-02-10 | 2021-08-25 | Roche Glycart Ag | Mutantiniai interleukino-2 polipeptidai |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
CN104411717A (zh) | 2012-01-09 | 2015-03-11 | 斯克利普斯研究所 | 具有超长cdr3s的人源化抗体 |
AU2013208003B2 (en) * | 2012-01-09 | 2017-12-14 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
MY175687A (en) | 2012-08-07 | 2020-07-06 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
CN104540848B (zh) * | 2012-08-08 | 2019-05-31 | 罗切格利卡特公司 | 白介素-10融合蛋白及其用途 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US9644021B2 (en) | 2013-01-11 | 2017-05-09 | The California Institute For Biomedical Research | Bovine fusion antibodies |
AU2014225307A1 (en) | 2013-03-08 | 2015-09-24 | The Curators Of The University Of Missouri | Methods and compositions for the treatment and/or prevention of type 1 diabetes |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
DK3019533T3 (da) | 2013-07-11 | 2020-03-23 | Scripps Research Inst | Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf |
EP3022224A2 (en) | 2013-07-18 | 2016-05-25 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
AU2014290361B2 (en) | 2013-07-18 | 2019-04-18 | Taurus Biosciences, Llc | Humanized antibodies with ultralong complementarity determining regions |
KR20160117463A (ko) * | 2014-02-06 | 2016-10-10 | 에프. 호프만-라 로슈 아게 | 인터루킨-10 면역접합체 |
HUE041530T2 (hu) | 2014-02-06 | 2019-05-28 | Hoffmann La Roche | Interleukin-2 fúziós fehérjék és alkalmazásaik |
-
2016
- 2016-12-01 JP JP2018528732A patent/JP6794448B2/ja active Active
- 2016-12-01 CU CUP2018000047A patent/CU20180047A7/es unknown
- 2016-12-01 BR BR112018010937-1A patent/BR112018010937A2/pt not_active IP Right Cessation
- 2016-12-01 US US15/367,003 patent/US10144768B2/en active Active
- 2016-12-01 SG SG11201804259UA patent/SG11201804259UA/en unknown
- 2016-12-01 AU AU2016362777A patent/AU2016362777B2/en not_active Ceased
- 2016-12-01 WO PCT/IB2016/057283 patent/WO2017093947A1/en active Application Filing
- 2016-12-01 CN CN201680080872.0A patent/CN108602870A/zh active Pending
- 2016-12-01 EA EA201891341A patent/EA201891341A1/ru unknown
- 2016-12-01 CA CA3006477A patent/CA3006477A1/en not_active Abandoned
- 2016-12-01 EP EP16810069.1A patent/EP3383891A1/en active Pending
- 2016-12-01 RU RU2018124307A patent/RU2018124307A/ru not_active Application Discontinuation
- 2016-12-01 UY UY0001037003A patent/UY37003A/es not_active Application Discontinuation
- 2016-12-01 KR KR1020187018601A patent/KR102213790B1/ko active IP Right Grant
- 2016-12-01 PE PE2018001044A patent/PE20181358A1/es unknown
- 2016-12-01 MX MX2018006778A patent/MX2018006778A/es unknown
- 2016-12-01 MA MA043372A patent/MA43372A/fr unknown
- 2016-12-01 KR KR1020217003359A patent/KR20210016479A/ko active Application Filing
- 2016-12-02 TW TW105139831A patent/TW201726716A/zh unknown
- 2016-12-02 AR ARP160103699A patent/AR106908A1/es unknown
-
2018
- 2018-05-22 IL IL259529A patent/IL259529A/en unknown
- 2018-05-28 CL CL2018001427A patent/CL2018001427A1/es unknown
- 2018-05-29 CO CONC2018/0005678A patent/CO2018005678A2/es unknown
- 2018-05-31 SA SA518391711A patent/SA518391711B1/ar unknown
- 2018-06-01 PH PH12018501160A patent/PH12018501160A1/en unknown
- 2018-06-15 EC ECIEPI201841733A patent/ECSP18041733A/es unknown
- 2018-10-18 US US16/163,857 patent/US11136366B2/en active Active
-
2020
- 2020-11-11 JP JP2020188307A patent/JP2021040637A/ja active Pending
-
2021
- 2021-08-26 US US17/458,028 patent/US20220127321A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR106908A1 (es) | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación | |
CO2017003408A2 (es) | Anticuerpos y fragmentos de los mismos como agonistas de gitr | |
CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
CL2018003153A1 (es) | Moléculas de anticuerpo para el tratamiento del cáncer. | |
UY36154A (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos | |
BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
AR089010A1 (es) | Anticuerpos anti-pd-l1 y sus usos | |
AR099289A1 (es) | Proteínas de fusión de interleucina-2 y usos de las mismas | |
CL2016002245A1 (es) | Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
CL2016000438A1 (es) | Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica | |
CL2017000113A1 (es) | Mutagénesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las mieloide d tipo 1 (trem-1) para reducir la viscocidad | |
CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
PE20200302A1 (es) | Proteinas de anticuerpo injertadas con citocinas y metodos de uso para trastornos relacionados con el sistema inmunitario | |
PE20170088A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
CO2019009080A2 (es) | Péptidos y métodos para el tratamiento de diabetes | |
EA201890439A1 (ru) | ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА) | |
UY37281A (es) | Variantes de gm-csf y métodos de uso | |
AR105945A1 (es) | Composiciones y métodos usados para aumentar la respuesta inmune y terapia del cáncer | |
AR101592A1 (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cd123 | |
AR108787A1 (es) | Variantes del factor estimulante de colonias de granulocitos y macrófagos (gm-csf) y sus métodos de uso | |
AR103227A1 (es) | Anticuerpos anti-csf1r para el tratamiento de svp | |
AR105714A1 (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
AR098848A1 (es) | Receptores de antígeno quimérico de mesotelina humana y usos de los mismos |